Cart
sales@molnova.com
Magnoflorine
CAS No. 2141-09-5
Magnoflorine( Magnoflorine | α-Magnoflorine | Thalictrine )
Catalog No. M17720 CAS No. 2141-09-5
Sinomeni Caulis et Rhizoma has sedative and anxiolytic effects, probably mediated by Magnoflorine through a GABAergic mechanism of action.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 57 | In Stock |
|
| 100MG | 261 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMagnoflorine
-
NoteResearch use only, not for human use.
-
Brief DescriptionSinomeni Caulis et Rhizoma has sedative and anxiolytic effects, probably mediated by Magnoflorine through a GABAergic mechanism of action.
-
DescriptionSinomeni Caulis et Rhizoma has sedative and anxiolytic effects, probably mediated by Magnoflorine through a GABAergic mechanism of action. Magnoflorine and Sinomenine have protective effects, are mediated by some mechanism other than prevention of micelle formation or protection of the erythrocyte membrane against osmotic imbalance.
-
In Vitro——
-
In Vivo——
-
SynonymsMagnoflorine | α-Magnoflorine | Thalictrine
-
PathwayCell Cycle/DNA Damage
-
Targetc-Myc
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number2141-09-5
-
Formula Weight342.41
-
Molecular FormulaC20H24NO4+
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[N+]1(CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)O)O)OC)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
CBL0137
CBL0137 (Curaxin CBL0137) is a histone chaperone FACT (facilitates chromatin transcription) and MYC signal inhibitor that markedly reduced tumor initiation and progression in vivo.
-
MYC inhibitor DC-34
MYC inhibitor DC-34 is a potent small molecule that selectively inhibits MYC at the transcriptional level only when a G-quadruplex (G4) is present in the promoter.
-
MYCi975
MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
